Efrat Dotan, MD
Medical Oncology · Philadelphia, PANPI 1740312990
Payments from drug & device makers
Across 231 payments — averaging $27,526 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$5.4M
- AstraZeneca$463K
- Incyte Corporation$217K
- Merck$102K
- GSK$78K
- E.r. Squibb & Sons, L.L.C.$41K
- plus $59K from 16 others
Across 2 payments — averaging $1900.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 9 | $5,398,277 |
| AstraZeneca | 23 | $463,476 |
| Incyte Corporation | 123 | $217,029 |
| Merck | 12 | $101,992 |
| GSK | 9 | $77,690 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40,768 |
| Beigene, Ltd. | 9 | $11,671 |
| Olympus Corporation | 14 | $10,708 |
| Pfizer | 6 | $7,763 |
| Beone Medicines Ltd. | 1 | $7,724 |
| Amgen | 2 | $5,340 |
| Array Biopharma Inc | 4 | $3,813 |
| AbbVie | 2 | $3,650 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $2,340 |
| G1 Therapeutics, Inc. | 2 | $2,057 |
| Jazz Pharmaceuticals Inc. | 2 | $2,040 |
| Taiho Oncology, Inc. | 2 | $1,742 |
| Olympus Corporation Of The Americas | 4 | $300 |
| Genentech USA, Inc. | 1 | $46 |
| Vapotherm Inc | 1 | $27 |
| Lilly USA, LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
How this compares
$6,358,493 in reported general payments places this provider in the 90th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Philadelphia
- Sukhmani PaddaPhiladelphia$25.6M
- Peter O DwyerPhiladelphia$18M
- Margaret von MehrenPhiladelphia$17.4M
- Kim Reiss BinderPhiladelphia$16.9M
- Carl JunePhiladelphia$13M
- Takami SatoPhiladelphia$11.5M
- Vivek NarayanPhiladelphia$10.6M
- Ubaldo Martinez-OutschoornPhiladelphia$10.5M
- Neil PalmisianoPhiladelphia$10.1M
- Anthony OlszanskiPhiladelphia$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.